Background
==========

Nasopharyngeal carcinoma is a head and neck cancer characterized as highly malignancy and regional selection \[[@b1-medscimonit-22-2215],[@b2-medscimonit-22-2215]\]. NPC is a rare cancer in Western countries, but it is common in Asian countries \[[@b3-medscimonit-22-2215]\]. NPC frequently occurs in southern China, included Guangdong, Fujian, Hong Kong and Southeast Asia, including Malaysia, Indonesia, and Singapore.

The incidence rate of NPC is 2 per 100 000 worldwide \[[@b4-medscimonit-22-2215]\]. The NPC incidence in southern China is 20--50 times higher than in Western countries \[[@b5-medscimonit-22-2215]\]. Radiotherapy is the main curative treatment for NPC to extend patient survival time \[[@b6-medscimonit-22-2215],[@b7-medscimonit-22-2215]\]. NPC presents highly malignant recurrence with local tissue invasion and distant metastasis, which is the dominant reason for radiotherapy failure \[[@b8-medscimonit-22-2215]\].

Currently, the major etiological factors of NPC are reported to be genetic susceptibility, environmental factors, and Epstein-Barr virus (EBV) infection. Familial and large-scale case-control studies report that HLA class I genes in the MHC locus at chromosome 6p21 are notably associated with high risk of NPC. In addition, CDK5, TEL2, CELF2, and IKKB \[[@b9-medscimonit-22-2215]--[@b12-medscimonit-22-2215]\] are also reported to be associated with NPC pathogenesis. Environmental risk factors include eating salt-preserved food \[[@b13-medscimonit-22-2215]\], insufficient intake of fresh vegetables and fruits \[[@b14-medscimonit-22-2215]\], alcohol consumption \[[@b15-medscimonit-22-2215]\], and tobacco smoking \[[@b13-medscimonit-22-2215],[@b16-medscimonit-22-2215]\]. Epstein-Barr virus (EBV) infection is an extensively researched etiological factor for NPC. EBV belongs to the gamma herpes virus family, persistently infects B lymphocytes in more than 90% of adults, and is related to NPC tumorigenesis \[[@b17-medscimonit-22-2215]\].

In addition to the above-mentioned etiological factors of NPC, mounting evidence shows that microRNAs (miRNAs) may play essential roles in NPC tumorigenesis by regulating target genes. miRNAs are small (20--25 nucleotides) non-coding RNAs that negatively regulate expression level of target gene \[[@b18-medscimonit-22-2215]\]. Numerous studies have reported that miRNAs are associated with NPC cell proliferation, migration, invasion, metastasis, and irradiation sensitivity by suppressing their target genes. miR-142-3p promotes NPC cell proliferation via suppressing SOCS6 expression \[[@b19-medscimonit-22-2215]\]. miR-4649-3p inhibits NPC cell proliferation by targeting protein tyrosine phosphatase SHP-1 \[[@b20-medscimonit-22-2215]\]. miR-29a/b regulates SPARC and COL3A1 gene expression to promote NPC cell migration and invasion \[[@b21-medscimonit-22-2215]\]. miR-23a targets IL-8/Stat3 pathway results in radio-sensitivity in NPC \[[@b22-medscimonit-22-2215]\], while miR-504 down-regulates nuclear respiratory factor 1 result in radio-resistance in NPC \[[@b23-medscimonit-22-2215]\]. However, the mechanism of pathogenesis in NPC remains unclear.

In this study we used bioinformatics methods to integrate miRNA and mRNA expression data, which are available in the GEO database, to identify differentially expressed miRNAs and target genes between NPC and normal control tissues, aiming to provide valuable information for use in defining the mechanism of pathogenesis in NPC.

Material and Methods
====================

Gene expression datasets
------------------------

We searched the Gene Expression Omnibus database (GEO, *<http://www.ncbi.nlm.nih.gov/geo>*) for mRNA and miRNA expression profiling of NPC, and downloaded the raw expression data. GEO is a public repository for high-throughput gene expression data \[[@b24-medscimonit-22-2215]\]. We only retained the microarray studies between tumor and normal tissues. The following information was extracted from each identified study: GEO accession number, platform, number of cases and controls, time, and author.

Data processing
---------------

Different sequencing platforms and clinical samples commonly cause the heterogeneity among different microarray datasets, and make it difficult to compare microarray datasets directly. We downloaded the raw expression dataset and preprocessed it by log2 transformation and Z-score normalization.

Analysis of differentially expressed miRNA and mRNA
---------------------------------------------------

The miRNAs and mRNA differentially expressed between the NPC and normal control samples were identified using the limma method, which is a linear model for microarray data analysis \[[@b25-medscimonit-22-2215]\]. We selected differentially expressed miRNA as false discovery rate (FDR) \<0.05, and selected differentially expressed mRNA as FDR \<0.001.

Identification of miRNA target genes
------------------------------------

To obtain the target genes of miRNAs, the selected miRNAs were integrated into the miRWalk database (*<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/>*) \[[@b26-medscimonit-22-2215]\], in which the correlation between target genes and miRNAs have been confirmed. miRWalk is a comprehensive database that provides predicted and experimentally validated miRNA-target interactions for humans, mice, and rats. It combines the predicted and validated information with a comparison of binding sites resulting from 12 existing miRNA-target prediction programs \[[@b26-medscimonit-22-2215],[@b27-medscimonit-22-2215]\]. In our study, we used 6 algorithms: DIANAmT, miRanda, miRDB, miRWalk, PICTAR, and TargetScan to predict target genes of miRNA; if more than 4 of 6 algorithms predicted the same gene of miRNA, the gene was considered as a target gene of the miRNA \[[@b26-medscimonit-22-2215]\]. Reverse correlations of miRNA-target gene interacting pairs were subject to construct miRNA-RNA interaction network analysis.

miRNA-target gene network
-------------------------

Differentially expressed miRNA and differentially expressed target genes were used to construct the interaction network by using Cytoscape software (*<http://cytoscape.org>*) \[[@b28-medscimonit-22-2215]\]. In the miRNA-gene network, a circular node represented the mRNA and a diamond node represented the miRNA, and their association was represented by a line.

Functional enrichment analysis
------------------------------

The underlying function of differentially expressed target genes was predicted by the Gene Ontology (GO) \[[@b29-medscimonit-22-2215]\] function and Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@b30-medscimonit-22-2215]\] pathway enrichment analysis using the DAVID tool (Database for Annotation, Visualization, and Integrated Discovery) (*<http://www.david.niaid.nih.gov>*) \[[@b31-medscimonit-22-2215]\]. We set p\<0.05 and FDR \<0.05 as the cut-off for selecting significantly enriched functional GO terms and KEGG pathway, respectively.

Quantitative real-time polymerase chain reaction (qRT-PCR)
----------------------------------------------------------

Total RNA of fresh frozen tissues was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The SuperScript III Reverse Transcription Kit (Invitrogen, Carlsbad, CA, USA) was used to synthesize the cDNA according to the manufacturer's instructions. qRT-PCR reactions were performed using Power SYBR Green PCR Master Mix \[[@b32-medscimonit-22-2215]\] (Applied Biosystems, Foster City, CA) on the Applied Biosystems 7500 (Applied Biosystems, Foster City, CA). The miRcute miRNA First-Strand cDNA Kit (Tiangen, Beijing, China) and miRcute miRNA qPCR Detection Kit (Tiangen, Beijing, China) were used for miRNA expression level detection. U6 and β-actin were used as internal control for miRNA and mRNA detected. The relative expression of target genes was calculated using the 2^−ΔΔCT^ equation. The PCR primers were used as shown in [Table 1](#t1-medscimonit-22-2215){ref-type="table"}.

Statistical analysis
--------------------

At least 3 independent experiments were performed for statistical evaluation. qRT-PCR experimental data were expressed as means ±SD. The statistical significance was evaluated using the Student's t-test and p\<0.05 was considered as a significant difference.

Results
=======

Differentially expressed miRNAs and mRNAs in the NPC
----------------------------------------------------

In this work, we collected a total of 3 mRNA expression profiles including 74 NPC and 31 normal control (NC) samples and 5 miRNA expression profiling including 402 NPC and 38 NC samples, as shown in [Table 2](#t2-medscimonit-22-2215){ref-type="table"}. After normalization of the raw microarray data, significantly differentially expressed genes including 27 miRNA and 982 mRNA were identified in NPC compared to normal nasopharyngeal tissues; 27 miRNAs consisted of 12 up-regulated and 15 down-regulated miRNAs; 982 mRNA consisted of 547 up-regulated and 435 down-regulated mRNAs ([Supplementary Table 1](#s1-medscimonit-22-2215){ref-type="supplementary-material"}). hsa-miR-205, hsa-miR-196b, and hsa-miR-632 was the most significantly up-regulated miRNAs, while hsa-miR-130a, hsa-let-7a, and hsa-miR-34b were the most significantly down-regulated miRNAs in NPC compared with the normal control ([Table 3](#t3-medscimonit-22-2215){ref-type="table"}).

The interaction network of miRNAs and target genes
--------------------------------------------------

Based on the identified miRNA-target gene interaction pairs of reverse association, we compared the interaction network between miRNAs and target genes in NPC and visualized them with Cytoscape software. We used 1185 miRNA-target gene pairs of reverse correlation, including 316 pairs of up-regulated miRNA and 735 pairs of down-regulated miRNA, to construct the miRNA-target genes interaction network. The target predictions of hsa-miR-376a\*and hsa-miR-18a\* are not available in miRWalk databases.

In this network, the significantly differentially expressed hsa-miR-632, hsa-miR-205, hsa-miR-18b, hsa-miR-34b, and hsa-miR-130a were targeted in significantly differentially expressed PIGR, CDC6, CD22, SMPD3 and DTX4, respectively, as shown in [Figure 1](#f1-medscimonit-22-2215){ref-type="fig"}.

GO classification of miRNA target genes
---------------------------------------

To obtain insights into the biological roles of differentially expressed miRNA target genes, we analyzed the predicted target gene of miRNAs using GO annotation. The threshold of GO terms was p-value\<0.05. Nuclear division (GO: 0000280, p=3.05E-05) and cell cycle G2/M phase transition (GO: 0044839, p=4.02E-05) were the most significant enrichments of targets genes biological process. Intracellular organelle part (GO: 0044446, p=1.95E-05) and organelle part (GO: 0044422, p=3.62E-05) were the highest enrichments of cellular component. Catalytic activity (GO: 0003824, p=1.09E-04) and hydrolase activity (GO: 0016787, p=1.75E-04) were the highest enrichments of molecular function, as shown in [Table 4](#t4-medscimonit-22-2215){ref-type="table"}.

Pathway analysis of miRNA target genes
--------------------------------------

We performed the KEGG pathway enrichment analysis for differentially expressed miRNA-target genes. FDR \<0.05 was used as the criteria for pathway detection. The highest enrichment of pathways in our analysis was the pathway in cancer (FDR=1.78E-11) and cell cycle (FDR=1.48E-07) ([Table 5](#t5-medscimonit-22-2215){ref-type="table"}).

qRT-PCR validation of differentially expressed miRNAs and target genes
----------------------------------------------------------------------

To validate the microarray analysis data, the levels of significantly differentially expressed miRNAs (hsa-miR-632, hsa-miR-34b, hsa-miR-130a, hsa-miR-205, and hsa -miR-18b) and target genes (CD22, CDC6, DTX4, PIGR, and SMPD3) were quantified by qRT-PCR in 2 NPC samples and 2 normal control samples. As shown in [Figure 2A--2C](#f2-medscimonit-22-2215){ref-type="fig"}, the expression levels of hsa-miR-632, hsa-miR-205, and hsa-miR-18b were significantly up-regulated and the respective target genes CD22, PIGR, and SMPD3 were significantly down-regulated in NPC samples (p\<0.01). The expressions of hsa-miR-34b and hsa-miR-130a were significantly down-regulated and the respective target genes CDC6 and DTX4 were significantly up-regulated in NPC samples (p\<0.01), as shown in [Figure 2D, 2E](#f2-medscimonit-22-2215){ref-type="fig"}. In conclusion, the qRT-PCR validation of differentially expressed miRNAs and target genes between NPC and normal control samples was in accordance with results of our microarray data bioinformatics analysis.

Discussion
==========

miRNAs play essential roles in many fundamental biological processes, including cell proliferation, migration, invasion, and metastasis. miRNAs can function as oncogenes or oncosuppressor, depending on the targets suppressed.

In our study, we found that hsa-miR-205, hsa-miR-632, hsa-miR-196b, hsa-miR-18b, and hsa-miR-93 are the top 5 up-regulated miRNAs and we found that hsa-miR-130a, hsa-let-7a, hsa-miR-34b, hsa-let-7e, and hsa-let-7d are the top 5 down-regulated miRNAs in NPC patients. hsa-miR-205 and hsa-miR-18a are significantly up-regulated, and hsa-miR-34b is significantly down-regulated in NPC biopsy tissues \[[@b33-medscimonit-22-2215],[@b34-medscimonit-22-2215]\], which is in accordance with our bioinformatics analysis and further was validated through qRT-PCR ([Table 3](#t3-medscimonit-22-2215){ref-type="table"}, [Figure 2D](#f2-medscimonit-22-2215){ref-type="fig"}). Moreover, hsa-miR-205 and hsa-miR-34b expression level influence the development of NPC \[[@b33-medscimonit-22-2215]\]. Functions of hsa-miR-632 up-regulation and hsa-miR-130a down-regulation in NPC are not reported.

Tang et al. reported that miR-205-5p has significant diagnostic value as a novel candidate biomarker in NPC. They performed a comprehensive analysis of microRNA expression patterns of 3 NPC biopsies and 3 normal nasopharyngeal epithelium specimens, then validated the differentially expressed miRNAs in 67 NPC and 25 normal tissues with qRT-PCR, finding that miR-205-5p is 1 of 5 significantly differentially expressed miRNAs in NPC \[[@b35-medscimonit-22-2215]\]. In addition, miR-205 is related to radio-resistance of NPC, and miR-205 up-regulation results in radio-resistance of NPC through suppressing the PTEN pathway \[[@b36-medscimonit-22-2215],[@b37-medscimonit-22-2215]\]. In our work, PIGR was predicted as target gene of miR-205, and this was validated in NPC tissues by qRT-PCR ([Figure 2B](#f2-medscimonit-22-2215){ref-type="fig"}). PIGR had significantly lower expression in NPC specimens, but was frequently expressed in non-tumor controls \[[@b38-medscimonit-22-2215]\], which is consistent with our results ([Figure 2B](#f2-medscimonit-22-2215){ref-type="fig"}).

Target CDC6 was up-regulated by hsa-miR-34b in NPC tissues, as [Figure 2D](#f2-medscimonit-22-2215){ref-type="fig"} shows. miR-34b/c and TP-53 polymorphisms may contribute to the risk of NPC, and gene-gene interaction of miR-34b/c rs4938723 and TP-53 Arg72-Pro increases the risk of NPC \[[@b39-medscimonit-22-2215]\]. It is reported that CDC6 is associated with cancer prognosis and proliferation, while CDC6 functions in NPC are not reported. CDC6 is significantly up-regulated by miR-26a/b in lung cancer specimens compared with the adjacent normal tissues, suggesting that CDC6 is associated with poorer prognosis of lung cancer \[[@b40-medscimonit-22-2215]\]. Knockdown of CDC 6 effectively inhibits proliferation of tongue squamous cell carcinoma Tca8113 cells \[[@b41-medscimonit-22-2215]\]. In our work, CDC6 was enriched in cell cycle, which is the top 2 KEGG enrichment pathway of differentially expressed miRNA target genes ([Table 5](#t5-medscimonit-22-2215){ref-type="table"}).

hsa-miR-18b was up-regulated and consequentially caused significant down-regulation of target genes ABLIM1 and SMPD3 (NSMASE2) in NPC ([Table 3](#t3-medscimonit-22-2215){ref-type="table"}, [Figure 2C](#f2-medscimonit-22-2215){ref-type="fig"}). SMPD3 was down-regulated by both of hsa-miR-18b and hsa-miR-632 in our study. hsa-miR-18b influences cancer cell proliferation, growth, and metastasis, while hsa-miR-18b up-regulation is mediated by loss of connective tissue growth factor through PI3K/AKT/C-Jun and C-Myc signaling to promote cell growth and cell proliferation of NPC \[[@b42-medscimonit-22-2215]\]. Oxidative stress modulates NSMASE2 sub-cellular localization in plasma membranes to generate ceramide and induces apoptosis of lung carcinoma A549 cell line \[[@b43-medscimonit-22-2215]\]. NSMASE2 regulates exosomal miRNA secretion and promotes angiogenesis within the tumor microenvironment, as well as in metastasis \[[@b44-medscimonit-22-2215]\].

Deltex 4, E3 ubiquitin ligase is the official name of DTX4; it functions as a negative regulator of Notch signaling \[[@b45-medscimonit-22-2215]\], which is crucial for the T-cell development in early stages and angiogenesis during carcinogenesis \[[@b46-medscimonit-22-2215],[@b47-medscimonit-22-2215]\]. Dysregulation of Notch and Wnt promotes cell differentiation and tumorigenesis. In our study, DTX4 was up-regulated by hsa-miR-130a, hsa-miR-7a, hsa-miR-7g, hsa-miR-7d, and hsa-miR-7e in NPC patients.

CD22 was down-regulated by both of hsa-miR-632 and hsa-miR-210. CD22 was enriched in B cell receptor and hematopoietic cell lineage signaling pathway via KEGG pathway analysis ([Table 5](#t5-medscimonit-22-2215){ref-type="table"}). It is reported that pan-B lymphocytes have scant peri-tumoral areas and are absent in 29 out of 50 NPC biopsies through using immunohistological detection \[[@b48-medscimonit-22-2215]\]. hsa-miR-632 is reportedly associated with breast cancer tumorigenesis, and high expression level of hsa-miR-632 down-regulates DNAJB6, leading to significantly increased invasive and metastatic ability of breast cancer cells compared to mammary epithelial cells \[[@b49-medscimonit-22-2215]\].

Pathway in cancer was identified as the most significantly enriched pathway in NPC ([Table 5](#t5-medscimonit-22-2215){ref-type="table"}). Pathway in cancer is related to pathogenesis of various cancer types, such as colorectal, pancreatic, thyroid, and lung cancer \[[@b50-medscimonit-22-2215]--[@b54-medscimonit-22-2215]\], indicating that pathways in cancer may play an important role in NPC pathogenesis.

There are limitations in our work. We have constructed the regulatory network of miRNAs and mRNA inverse correlations pairs, and the pathogenesis of key miRNAs and mRNAs in NPC need to be elucidated through *in vivo* and *in vitro* experiments.

Conclusions
===========

We identified 27 differentially expressed miRNAs and 982 differentially expressed mRNAs between NPC and normal tissues. We used 1185 miRNA-target gene pairs of inverse correlations to construct an interaction network. In this network, we found several miRNAs and genes that may play important roles in NPC, such as hsa-miR-205, hsa-miR-34b, hsa-miR-18b, hsa-miR-632, hsa-miR-130a, PIGR, CDC6, CD22, SMPD3, and DTX4. The pathway in cancer may be involved in the pathogenesis mechanism of NPC. Our findings may provide an important contribution to further elucidate the pathogenesis mechanisms of NPC.

Supplementary materials
=======================

###### 

Full list of differentially expressed mRNA in nasopharyngeal carcinoma.

  Genes          FDR        Up/down regulation
  -------------- ---------- --------------------
  LMNB2          1.00E−11   Up
  HDGFRP3        2.32E−11   Up
  FJX1           2.89E−11   Up
  RBBP8          4.91E−11   Up
  LHX2           5.18E−11   Up
  TNFAIP6        8.16E−11   Up
  ECT2           1.02E−10   Up
  C12orf48       1.74E−10   Up
  CHAF1B         2.93E−10   Up
  VRK2           4.51E−10   Up
  NFE2L3         8.20E−10   Up
  TFRC           1.08E−09   Up
  NPL            1.08E−09   Up
  FAM64A         1.42E−09   Up
  GALNT11        2.59E−09   Up
  TNFSF4         2.98E−09   Up
  GPSM2          3.06E−09   Up
  MAD2L1         4.03E−09   Up
  GAD1           4.59E−09   Up
  CDC6           5.29E−09   Up
  PFDN4          5.31E−09   Up
  ATF5           6.91E−09   Up
  MRPL42         7.85E−09   Up
  ZWILCH         8.93E−09   Up
  FOXM1          9.23E−09   Up
  RAN            1.00E−08   Up
  OLA1           1.31E−08   Up
  OIP5           1.99E−08   Up
  PSRC1          2.17E−08   Up
  FAP            2.17E−08   Up
  MINPP1         2.86E−08   Up
  SEC61A2        3.30E−08   Up
  CCNF           3.30E−08   Up
  C12orf5        4.54E−08   Up
  ARNT2          4.54E−08   Up
  RIF1           4.86E−08   Up
  RCN2           5.33E−08   Up
  DTX4           6.03E−08   Up
  RAD54B         7.31E−08   Up
  CLASP1         7.31E−08   Up
  KIF14          7.46E−08   Up
  GNPDA1         7.46E−08   Up
  EXO1           7.46E−08   Up
  PMAIP1         8.23E−08   Up
  KCTD3          1.10E−07   Up
  GRB10          1.31E−07   Up
  GINS3          1.63E−07   Up
  PTGS2          1.69E−07   Up
  PUS7           1.82E−07   Up
  XPOT           2.00E−07   Up
  PLA2G3         2.04E−07   Up
  PALB2          2.20E−07   Up
  PRMT3          2.36E−07   Up
  SAC3D1         2.45E−07   Up
  VCAN           2.52E−07   Up
  FGF1           2.78E−07   Up
  ESM1           2.78E−07   Up
  C12orf11       2.86E−07   Up
  P4HA1          3.59E−07   Up
  PBK            3.83E−07   Up
  RNASEH2A       3.91E−07   Up
  DOCK4          3.91E−07   Up
  CNIH4          3.91E−07   Up
  NUAK1          3.91E−07   Up
  AHCY           3.99E−07   Up
  TBCE           4.26E−07   Up
  UBE2S          4.33E−07   Up
  COL5A1         4.39E−07   Up
  NOX4           4.49E−07   Up
  GAPDH          4.52E−07   Up
  EIF4E2         4.52E−07   Up
  DTL            4.52E−07   Up
  STK3           4.94E−07   Up
  PSMD14         4.94E−07   Up
  DSG2           4.94E−07   Up
  CENPF          5.08E−07   Up
  PTTG3P         5.15E−07   Up
  FANCL          5.16E−07   Up
  PPIF           5.26E−07   Up
  PSMA4          5.52E−07   Up
  HDAC2          6.06E−07   Up
  MCM4           6.38E−07   Up
  CKS1B          6.38E−07   Up
  UCK2           6.89E−07   Up
  EIF2S2         6.90E−07   Up
  TIPIN          7.68E−07   Up
  FSCN1          7.68E−07   Up
  HSPE1          7.86E−07   Up
  MMP12          8.05E−07   Up
  TMEM194A       8.19E−07   Up
  KIF18A         8.22E−07   Up
  INSM1          8.24E−07   Up
  RAI14          8.77E−07   Up
  UNG            9.44E−07   Up
  PIK3CB         1.12E−06   Up
  TRIP6          1.15E−06   Up
  MTX2           1.21E−06   Up
  CEP152         1.27E−06   Up
  STAR           1.30E−06   Up
  PLAU           1.37E−06   Up
  HOMER3         1.38E−06   Up
  ME3            1.39E−06   Up
  RIC8B          1.40E−06   Up
  ZFP64          1.56E−06   Up
  NUP155         1.58E−06   Up
  TOMM40         1.65E−06   Up
  PGAP1          1.67E−06   Up
  ITGAV          1.88E−06   Up
  KIF4A          1.90E−06   Up
  SRD5A1         2.03E−06   Up
  ZNF124         2.17E−06   Up
  RAD51AP1       2.17E−06   Up
  PTTG1          2.26E−06   Up
  BRCA2          2.31E−06   Up
  GGCT           2.35E−06   Up
  ANXA4          2.41E−06   Up
  ADA            2.74E−06   Up
  TMEM14A        2.77E−06   Up
  PAK1IP1        3.08E−06   Up
  TMEM33         3.10E−06   Up
  HSPD1          3.11E−06   Up
  GORASP1        3.11E−06   Up
  USP18          3.12E−06   Up
  MARK1          3.14E−06   Up
  SLC39A6        3.17E−06   Up
  ZNF562         3.39E−06   Up
  CDC25C         3.48E−06   Up
  RPE            3.50E−06   Up
  POLQ           3.50E−06   Up
  SNRPF          3.79E−06   Up
  SSX2IP         3.81E−06   Up
  STAP2          3.84E−06   Up
  CDC45          3.84E−06   Up
  POMGNT1        3.86E−06   Up
  BID            3.88E−06   Up
  STC2           4.00E−06   Up
  BRIP1          4.00E−06   Up
  TM7SF3         4.21E−06   Up
  DUSP10         4.50E−06   Up
  PSMG1          4.62E−06   Up
  CCL4           4.74E−06   Up
  MED21          4.88E−06   Up
  NOV            5.14E−06   Up
  SUMO1          5.21E−06   Up
  CPOX           5.30E−06   Up
  COL7A1         5.30E−06   Up
  CAT            5.39E−06   Up
  STIL           5.84E−06   Up
  CCT2           5.93E−06   Up
  DNM1L          5.95E−06   Up
  SLC25A13       6.29E−06   Up
  IMPACT         6.52E−06   Up
  CACYBP         6.61E−06   Up
  RGS4           6.63E−06   Up
  PHF14          7.10E−06   Up
  ILF2           7.10E−06   Up
  ENO1           7.13E−06   Up
  PAIP1          7.30E−06   Up
  TNFSF15        7.34E−06   Up
  EPHB4          7.34E−06   Up
  ATP6V1B2       7.34E−06   Up
  OAS3           7.83E−06   Up
  GSTO1          7.93E−06   Up
  TPI1           7.99E−06   Up
  IL15RA         8.23E−06   Up
  HOXA7          8.40E−06   Up
  SETD2          8.66E−06   Up
  C1QB           8.95E−06   Up
  IFRD1          9.15E−06   Up
  NT5M           9.92E−06   Up
  PITPNB         1.01E−05   Up
  CENPN          1.02E−05   Up
  GPR137B        1.03E−05   Up
  TK1            1.05E−05   Up
  TMEFF1         1.09E−05   Up
  SULF1          1.12E−05   Up
  ERCC6L         1.13E−05   Up
  DENR           1.21E−05   Up
  C5orf13        1.21E−05   Up
  ATP2C1         1.22E−05   Up
  STAT1          1.27E−05   Up
  TTK            1.30E−05   Up
  SS18L1         1.30E−05   Up
  GABPB1         1.30E−05   Up
  BIRC5          1.33E−05   Up
  WNT2           1.38E−05   Up
  HRSP12         1.42E−05   Up
  SNRPG          1.46E−05   Up
  PFDN2          1.48E−05   Up
  POLR3D         1.54E−05   Up
  GJB1           1.57E−05   Up
  POGLUT1        1.58E−05   Up
  TNIP3          1.63E−05   Up
  PSMB3          1.64E−05   Up
  YWHAQ          1.69E−05   Up
  NCBP2          1.80E−05   Up
  PLD3           1.80E−05   Up
  TWSG1          1.87E−05   Up
  SKP2           2.00E−05   Up
  YWHAH          2.03E−05   Up
  CASP6          2.08E−05   Up
  IRF6           2.10E−05   Up
  CKAP4          2.12E−05   Up
  SLC5A6         2.20E−05   Up
  GPI            2.27E−05   Up
  C1orf112       2.29E−05   Up
  MYC            2.32E−05   Up
  NIT2           2.40E−05   Up
  LGR4           2.49E−05   Up
  HOXC6          2.53E−05   Up
  FPR3           2.53E−05   Up
  GLT25D1        2.56E−05   Up
  RACGAP1        2.62E−05   Up
  MIF            2.65E−05   Up
  CXCL3          2.69E−05   Up
  CTPS           2.73E−05   Up
  FGD6           2.75E−05   Up
  FNDC3B         2.76E−05   Up
  LHFPL2         2.81E−05   Up
  CDC25A         2.90E−05   Up
  CD70           2.97E−05   Up
  TOMM70A        3.03E−05   Up
  COPS2          3.12E−05   Up
  CCND2          3.12E−05   Up
  MARCO          3.17E−05   Up
  WDR41          3.40E−05   Up
  TAF5           3.40E−05   Up
  AP3M2          3.49E−05   Up
  TMEM39A        3.55E−05   Up
  TMEM185B       3.55E−05   Up
  PLK4           3.64E−05   Up
  COL10A1        3.64E−05   Up
  C11orf41       3.68E−05   Up
  KITLG          3.70E−05   Up
  PLOD1          3.79E−05   Up
  UBFD1          3.79E−05   Up
  NFKBIA         3.79E−05   Up
  CORO1C         3.85E−05   Up
  MORC4          3.95E−05   Up
  HOXA10         3.98E−05   Up
  MRPL13         4.11E−05   Up
  GINS1          4.17E−05   Up
  ZFP112         4.20E−05   Up
  EXT1           4.23E−05   Up
  KIF13A         4.25E−05   Up
  TMEM97         4.31E−05   Up
  PIK3CD         4.44E−05   Up
  IFIT3          4.59E−05   Up
  ETV7           4.76E−05   Up
  NCAPD3         4.77E−05   Up
  ANGPT2         4.83E−05   Up
  SNRPD1         5.10E−05   Up
  NDUFA9         5.24E−05   Up
  TMPO           5.33E−05   Up
  CD14           5.38E−05   Up
  CDK5           5.44E−05   Up
  DKC1           5.55E−05   Up
  ASB9           5.76E−05   Up
  TRMT61B        5.82E−05   Up
  C1QBP          5.91E−05   Up
  WRN            5.97E−05   Up
  TMEM106C       5.97E−05   Up
  SYNE1          6.22E−05   Up
  ICAM1          6.27E−05   Up
  FAM60A         6.41E−05   Up
  SRSF9          6.72E−05   Up
  PRR5L          6.72E−05   Up
  MLF1IP         6.78E−05   Up
  GNL2           6.80E−05   Up
  PSMB2          6.94E−05   Up
  ASPN           7.03E−05   Up
  YRDC           7.17E−05   Up
  KPNA2          7.25E−05   Up
  TYROBP         7.30E−05   Up
  EXOSC5         7.33E−05   Up
  TNFRSF9        7.34E−05   Up
  GAS8           7.37E−05   Up
  TBCA           7.38E−05   Up
  FAM162A        7.38E−05   Up
  MAPKAPK5       7.41E−05   Up
  POSTN          7.82E−05   Up
  SSTR2          7.89E−05   Up
  SUPV3L1        8.01E−05   Up
  RSAD2          8.05E−05   Up
  RFC2           8.05E−05   Up
  H2AFZ          8.05E−05   Up
  UBE2V2         8.11E−05   Up
  MFHAS1         8.29E−05   Up
  SYNCRIP        8.60E−05   Up
  C17orf75       8.72E−05   Up
  WDR47          8.75E−05   Up
  FASTKD3        8.81E−05   Up
  NAA50          8.85E−05   Up
  ITGB1          8.94E−05   Up
  CAND1          9.04E−05   Up
  PTPN12         9.22E−05   Up
  MAT2A          9.40E−05   Up
  DERA           9.71E−05   Up
  KIAA0146       9.90E−05   Up
  EPCAM          9.97E−05   Up
  C12orf29       1.05E−04   Up
  PYCARD         1.06E−04   Up
  MDK            1.07E−04   Up
  BMP3           1.07E−04   Up
  RAB17          1.08E−04   Up
  PLAUR          1.08E−04   Up
  FASTKD2        1.09E−04   Up
  AIMP2          1.12E−04   Up
  WDR12          1.13E−04   Up
  ABCE1          1.13E−04   Up
  SERPINH1       1.15E−04   Up
  DEPDC1         1.16E−04   Up
  CYC1           1.18E−04   Up
  ITGB6          1.22E−04   Up
  PSMA7          1.23E−04   Up
  ZNF74          1.24E−04   Up
  SLMO2          1.24E−04   Up
  SCO2           1.24E−04   Up
  DMXL2          1.26E−04   Up
  BST2           1.26E−04   Up
  XPO1           1.27E−04   Up
  ENOPH1         1.27E−04   Up
  SCG5           1.28E−04   Up
  PAICS          1.29E−04   Up
  WASF1          1.31E−04   Up
  BCL2A1         1.32E−04   Up
  LGALS1         1.32E−04   Up
  RXRB           1.32E−04   Up
  RRM1           1.34E−04   Up
  PXDN           1.37E−04   Up
  PTRH2          1.38E−04   Up
  JMJD4          1.38E−04   Up
  MBD5           1.39E−04   Up
  RNF19B         1.40E−04   Up
  PRC1           1.43E−04   Up
  PRDM4          1.46E−04   Up
  NPM3           1.48E−04   Up
  UBE2Z          1.48E−04   Up
  KIF23          1.53E−04   Up
  RRN3           1.55E−04   Up
  ZNF532         1.58E−04   Up
  PIGA           1.58E−04   Up
  WBP5           1.59E−04   Up
  PIGN           1.59E−04   Up
  IL13RA2        1.60E−04   Up
  GTF3C3         1.60E−04   Up
  ARMC1          1.63E−04   Up
  NOL10          1.64E−04   Up
  COL4A5         1.65E−04   Up
  GADD45A        1.65E−04   Up
  FOXK2          1.71E−04   Up
  CCT3           1.71E−04   Up
  IDH1           1.72E−04   Up
  ADIPOR2        1.72E−04   Up
  PSMC4          1.72E−04   Up
  FCGR1B         1.72E−04   Up
  ROBO1          1.72E−04   Up
  CST1           1.74E−04   Up
  MEST           1.78E−04   Up
  CLSTN2         1.79E−04   Up
  UPF3B          1.81E−04   Up
  URB2           1.81E−04   Up
  TPT1           1.81E−04   Up
  FAH            1.81E−04   Up
  B4GALT2        1.82E−04   Up
  PPIA           1.82E−04   Up
  NME1           1.89E−04   Up
  AQP9           1.95E−04   Up
  UQCRH          1.96E−04   Up
  UBE2C          1.96E−04   Up
  MRPS35         1.97E−04   Up
  ADAM9          1.97E−04   Up
  DKK3           2.00E−04   Up
  RBL2           2.00E−04   Up
  DDX60          2.07E−04   Up
  ZBTB39         2.09E−04   Up
  MCTP2          2.13E−04   Up
  LOC100499177   2.13E−04   Up
  SCMH1          2.15E−04   Up
  CUEDC2         2.17E−04   Up
  ZNF140         2.17E−04   Up
  TAP1           2.18E−04   Up
  E2F6           2.20E−04   Up
  PA2G4          2.26E−04   Up
  BMP2           2.29E−04   Up
  DIABLO         2.35E−04   Up
  PSMD1          2.37E−04   Up
  CKAP5          2.41E−04   Up
  PRLR           2.43E−04   Up
  ERO1LB         2.44E−04   Up
  SPIN1          2.45E−04   Up
  PRNP           2.45E−04   Up
  PIWIL1         2.45E−04   Up
  TLN2           2.47E−04   Up
  SRP9           2.49E−04   Up
  SOCS5          2.52E−04   Up
  CCR1           2.55E−04   Up
  CEP76          2.58E−04   Up
  SCARB2         2.60E−04   Up
  MRPL12         2.65E−04   Up
  ISYNA1         2.66E−04   Up
  RPL32          2.70E−04   Up
  PKD2           2.70E−04   Up
  KAT2B          2.78E−04   Up
  TRIB1          2.80E−04   Up
  KDSR           2.84E−04   Up
  IFI44L         2.84E−04   Up
  UGCG           2.86E−04   Up
  POLR3G         2.89E−04   Up
  THBS2          2.97E−04   Up
  IGSF6          2.97E−04   Up
  STRAP          3.12E−04   Up
  EIF2AK2        3.14E−04   Up
  ADAM12         3.14E−04   Up
  SNX27          3.15E−04   Up
  KREMEN2        3.15E−04   Up
  CEP192         3.15E−04   Up
  PPP6C          3.21E−04   Up
  LOC730101      3.23E−04   Up
  PSMA6          3.25E−04   Up
  TGFBI          3.25E−04   Up
  PSTPIP2        3.25E−04   Up
  CCL8           3.28E−04   Up
  RPS29          3.29E−04   Up
  PLA2G7         3.30E−04   Up
  PNO1           3.32E−04   Up
  RARB           3.45E−04   Up
  CLIP2          3.45E−04   Up
  LAMP2          3.45E−04   Up
  CCT7           3.45E−04   Up
  ABTB2          3.45E−04   Up
  ABCA3          3.47E−04   Up
  NCK1           3.53E−04   Up
  CDK8           3.59E−04   Up
  WSB2           3.62E−04   Up
  DNMT3B         3.63E−04   Up
  EVL            3.69E−04   Up
  PTPLAD1        3.74E−04   Up
  GLA            3.81E−04   Up
  ADH5           3.88E−04   Up
  CDK4           3.94E−04   Up
  UMPS           3.99E−04   Up
  UCP2           3.99E−04   Up
  PTGES3         4.01E−04   Up
  LOC100127972   4.01E−04   Up
  FZD7           4.01E−04   Up
  TUBGCP4        4.04E−04   Up
  PPA1           4.07E−04   Up
  ARPC1A         4.08E−04   Up
  PDSS1          4.12E−04   Up
  IFIT1          4.17E−04   Up
  INPP1          4.17E−04   Up
  KCNE1          4.22E−04   Up
  PXMP2          4.24E−04   Up
  IL15           4.28E−04   Up
  PCSK7          4.33E−04   Up
  PRPF40A        4.34E−04   Up
  MLLT11         4.34E−04   Up
  MKKS           4.52E−04   Up
  NIPSNAP1       4.57E−04   Up
  TSR2           4.59E−04   Up
  LDHA           4.62E−04   Up
  CHCHD3         4.76E−04   Up
  NCAPH          4.82E−04   Up
  R3HDM1         4.98E−04   Up
  SPAST          4.98E−04   Up
  PDHX           5.01E−04   Up
  C2orf47        5.01E−04   Up
  CBX1           5.02E−04   Up
  PACS2          5.10E−04   Up
  C3AR1          5.23E−04   Up
  ANAPC10        5.24E−04   Up
  CCNJ           5.25E−04   Up
  TARS           5.41E−04   Up
  ATP5G3         5.49E−04   Up
  HSPA13         5.52E−04   Up
  TCF12          5.54E−04   Up
  EIF1AX         5.59E−04   Up
  CBX5           5.75E−04   Up
  YBX1           5.79E−04   Up
  CTSL1          5.82E−04   Up
  RFWD3          5.83E−04   Up
  ZNF473         5.84E−04   Up
  PDCD11         5.85E−04   Up
  TGIF2          5.86E−04   Up
  GSTK1          5.90E−04   Up
  GPR143         5.94E−04   Up
  NMD3           5.96E−04   Up
  JAG2           5.97E−04   Up
  DIAPH1         5.99E−04   Up
  GJA1           6.03E−04   Up
  KCNMB2         6.13E−04   Up
  ACOT7          6.15E−04   Up
  TMEM66         6.15E−04   Up
  REPIN1         6.18E−04   Up
  TRAP1          6.28E−04   Up
  SPDEF          6.32E−04   Up
  YTHDF3         6.46E−04   Up
  TNFAIP3        6.63E−04   Up
  SNRPE          6.63E−04   Up
  WDYHV1         6.64E−04   Up
  FNBP1L         6.64E−04   Up
  C6orf211       6.65E−04   Up
  ATP5B          6.65E−04   Up
  SEH1L          6.81E−04   Up
  EFNB2          6.81E−04   Up
  C1orf109       6.81E−04   Up
  SOX12          6.84E−04   Up
  SCAI           7.20E−04   Up
  ISG15          7.29E−04   Up
  RTF1           7.30E−04   Up
  ANKRD5         7.35E−04   Up
  AURKB          7.40E−04   Up
  DARS           7.52E−04   Up
  SUMO2          7.58E−04   Up
  WDR1           7.68E−04   Up
  LRP4           7.68E−04   Up
  MYO1B          7.73E−04   Up
  MCM10          7.73E−04   Up
  BYSL           7.73E−04   Up
  MMP1           7.81E−04   Up
  CCNE2          7.91E−04   Up
  ADAR           7.96E−04   Up
  MTCH2          7.97E−04   Up
  CHEK1          8.17E−04   Up
  XAF1           8.22E−04   Up
  LRP12          8.42E−04   Up
  PAFAH1B3       8.43E−04   Up
  STAMBP         8.44E−04   Up
  NRAS           8.54E−04   Up
  GHR            8.54E−04   Up
  ATP5J2         8.68E−04   Up
  HMGCR          8.75E−04   Up
  SENP2          8.78E−04   Up
  SLC35E3        9.08E−04   Up
  ORC1           9.19E−04   Up
  C5orf30        9.42E−04   Up
  GSTM2          9.49E−04   Up
  RSRC1          9.61E−04   Up
  DEGS1          9.70E−04   Up
  RPS6KC1        9.88E−04   Up
  RFC3           9.89E−04   Up
  ESPL1          9.93E−04   Up
  FKBP1A         9.96E−04   Up
  FBXO11         9.98E−04   Up
  EHBP1          9.98E−04   Up
  COL1A1         9.98E−04   Up
  DNALI1         0.00E+00   Down
  ALDH1L1        1.36E−12   Down
  SPAG8          4.00E−11   Down
  SCRN1          4.64E−11   Down
  FOXJ1          4.64E−11   Down
  CLU            4.64E−11   Down
  KLF2           1.91E−10   Down
  SCGB1A1        2.34E−10   Down
  SCGB2A1        2.93E−10   Down
  VPS11          6.74E−10   Down
  SYBU           8.20E−10   Down
  PDCD5          9.56E−10   Down
  GPR162         2.24E−09   Down
  STIM1          2.40E−09   Down
  SLC44A4        3.44E−09   Down
  PCYT2          3.97E−09   Down
  EPAS1          3.97E−09   Down
  ABLIM1         4.29E−09   Down
  MT3            4.59E−09   Down
  ATP2C2         5.67E−09   Down
  CRYL1          7.85E−09   Down
  C6orf97        7.93E−09   Down
  PROM1          8.64E−09   Down
  BLK            8.81E−09   Down
  B3GALT4        1.31E−08   Down
  CD22           1.88E−08   Down
  MSLN           1.99E−08   Down
  CIRBP          2.02E−08   Down
  WDR78          2.08E−08   Down
  MSRA           2.08E−08   Down
  PTGDS          2.47E−08   Down
  SLC16A7        3.25E−08   Down
  SMPD3          3.41E−08   Down
  CD1C           3.97E−08   Down
  VIPR1          4.54E−08   Down
  GNMT           6.09E−08   Down
  TCTA           7.46E−08   Down
  C10orf81       1.06E−07   Down
  PIGR           1.23E−07   Down
  IGHD           1.23E−07   Down
  FAM107A        1.23E−07   Down
  ASL            1.26E−07   Down
  NBEA           1.28E−07   Down
  AQP5           1.61E−07   Down
  SGSM3          1.66E−07   Down
  MSMB           1.76E−07   Down
  IK             1.78E−07   Down
  PDLIM2         2.21E−07   Down
  DDAH2          2.22E−07   Down
  FBXO22         2.29E−07   Down
  PIK3C2B        2.77E−07   Down
  VPREB3         3.67E−07   Down
  PDCD6IP        4.01E−07   Down
  TREML2         4.33E−07   Down
  FCRL2          4.33E−07   Down
  FAM174B        4.33E−07   Down
  DPEP2          4.52E−07   Down
  CLMN           4.87E−07   Down
  RNASE4         5.08E−07   Down
  PPP3CA         5.08E−07   Down
  GNG7           5.18E−07   Down
  AGR2           5.39E−07   Down
  GLTSCR2        5.44E−07   Down
  GALNT12        5.54E−07   Down
  ABHD14A        6.19E−07   Down
  KLHDC2         6.55E−07   Down
  C6orf103       7.80E−07   Down
  CD72           7.96E−07   Down
  AK1            8.20E−07   Down
  LXN            8.22E−07   Down
  FAM102A        8.56E−07   Down
  CR1            8.77E−07   Down
  CD1D           8.77E−07   Down
  MEIS3P1        8.84E−07   Down
  LMO2           1.01E−06   Down
  CYP2F1         1.04E−06   Down
  BAIAP3         1.05E−06   Down
  RPS6KA3        1.21E−06   Down
  WFDC2          1.24E−06   Down
  CD19           1.35E−06   Down
  BACE2          1.40E−06   Down
  DALRD3         1.41E−06   Down
  SIDT2          1.44E−06   Down
  PIP            1.61E−06   Down
  ABCB1          1.88E−06   Down
  FAM65B         1.90E−06   Down
  RRAGA          1.92E−06   Down
  AGBL2          2.06E−06   Down
  C5orf45        2.19E−06   Down
  E2F3           2.55E−06   Down
  SFMBT1         2.56E−06   Down
  TUBA4A         2.58E−06   Down
  BANK1          2.58E−06   Down
  TNFRSF13B      2.64E−06   Down
  HMGCL          2.67E−06   Down
  TTC12          2.84E−06   Down
  GCNT3          2.87E−06   Down
  VTCN1          2.88E−06   Down
  C10orf116      3.00E−06   Down
  MFNG           3.01E−06   Down
  CD180          3.10E−06   Down
  AHCTF1         3.12E−06   Down
  TFF3           3.13E−06   Down
  IQSEC1         3.17E−06   Down
  POU2AF1        3.24E−06   Down
  ENPP4          3.24E−06   Down
  BEND5          3.51E−06   Down
  CLDN10         3.59E−06   Down
  CD40LG         3.79E−06   Down
  ANG            4.04E−06   Down
  GPR110         4.04E−06   Down
  SERHL2         4.17E−06   Down
  ACAA1          4.21E−06   Down
  KAT5           4.62E−06   Down
  TBC1D22A       4.74E−06   Down
  FZD4           5.30E−06   Down
  ATP1A2         5.30E−06   Down
  KCNJ16         5.30E−06   Down
  HSPB8          5.99E−06   Down
  CCDC69         6.02E−06   Down
  CYB561D2       6.59E−06   Down
  TINF2          7.58E−06   Down
  ST6GAL1        7.74E−06   Down
  QARS           7.89E−06   Down
  SELENBP1       9.03E−06   Down
  CRY2           9.09E−06   Down
  DUSP26         9.93E−06   Down
  MPG            1.01E−05   Down
  COX7A1         1.02E−05   Down
  SWAP70         1.05E−05   Down
  MS4A1          1.05E−05   Down
  IFT88          1.09E−05   Down
  DND1           1.12E−05   Down
  KCNQ1          1.16E−05   Down
  CH25H          1.21E−05   Down
  LYL1           1.22E−05   Down
  SRPX           1.24E−05   Down
  NME5           1.30E−05   Down
  CEBPG          1.30E−05   Down
  PLA2G16        1.32E−05   Down
  ZNF395         1.41E−05   Down
  PLEKHB1        1.47E−05   Down
  C11orf71       1.49E−05   Down
  RAD51          1.54E−05   Down
  BEX4           1.63E−05   Down
  C3             1.71E−05   Down
  SMPD1          1.75E−05   Down
  CLCF1          1.76E−05   Down
  GPRIN2         1.77E−05   Down
  SGSM2          1.79E−05   Down
  CAND2          2.00E−05   Down
  WDHD1          2.10E−05   Down
  ARMCX6         2.10E−05   Down
  FGD2           2.18E−05   Down
  FMO2           2.21E−05   Down
  C6             2.35E−05   Down
  LMBRD1         2.53E−05   Down
  AK2            2.53E−05   Down
  ABCA7          2.71E−05   Down
  NXF2           2.75E−05   Down
  GABRP          2.82E−05   Down
  DNAH6          2.84E−05   Down
  CTDSP1         2.86E−05   Down
  PLAC8          2.97E−05   Down
  BCAS4          3.03E−05   Down
  BAALC          3.03E−05   Down
  GTF2F2         3.05E−05   Down
  VILL           3.12E−05   Down
  POLD4          3.17E−05   Down
  ITIH5          3.17E−05   Down
  DAZAP2         3.17E−05   Down
  SIGIRR         3.22E−05   Down
  EPHB6          3.30E−05   Down
  MEIS2          3.35E−05   Down
  ICAM3          3.35E−05   Down
  CCR6           3.35E−05   Down
  PSD4           3.49E−05   Down
  EFCAB1         3.64E−05   Down
  TGFBR3         3.78E−05   Down
  TMEM184B       3.84E−05   Down
  SPATA6         3.85E−05   Down
  CRLF1          3.95E−05   Down
  CLDN8          4.17E−05   Down
  ADCY2          4.30E−05   Down
  PIGH           4.32E−05   Down
  TFF1           4.33E−05   Down
  TSPAN1         4.55E−05   Down
  SIDT1          4.63E−05   Down
  PHF1           4.65E−05   Down
  ARHGAP44       4.76E−05   Down
  TMEM121        4.97E−05   Down
  CRIP2          4.99E−05   Down
  APOM           5.07E−05   Down
  FUCA1          5.18E−05   Down
  NEIL1          5.19E−05   Down
  LPAR1          5.20E−05   Down
  PSMA2          5.25E−05   Down
  LRIG1          5.32E−05   Down
  SRSF5          5.44E−05   Down
  ZFP106         5.54E−05   Down
  CRIP1          5.64E−05   Down
  MAST3          5.82E−05   Down
  DHX38          5.82E−05   Down
  PRKCB          6.01E−05   Down
  MRPL19         6.11E−05   Down
  ABCD4          6.37E−05   Down
  HSD17B8        6.72E−05   Down
  GPR18          6.72E−05   Down
  DNAH3          6.72E−05   Down
  ADAMTSL3       6.72E−05   Down
  INHBB          6.77E−05   Down
  NCR3           6.79E−05   Down
  CLDN3          6.79E−05   Down
  RNASE1         6.80E−05   Down
  CCNA1          6.86E−05   Down
  GOLGA8A        7.00E−05   Down
  PDZD2          7.03E−05   Down
  CCDC19         7.03E−05   Down
  EIF1B          7.25E−05   Down
  DLEC1          7.32E−05   Down
  EIF3J          7.41E−05   Down
  S1PR4          7.82E−05   Down
  ACTR10         7.96E−05   Down
  CHL1           7.99E−05   Down
  PPRC1          8.05E−05   Down
  TSPAN32        8.06E−05   Down
  LRRC23         8.06E−05   Down
  CGRRF1         8.29E−05   Down
  EFCAB6         8.32E−05   Down
  LAMB2          8.40E−05   Down
  CAP2           8.51E−05   Down
  DUSP22         8.73E−05   Down
  ADAM28         8.76E−05   Down
  LMAN1          8.77E−05   Down
  TDG            8.81E−05   Down
  AES            9.04E−05   Down
  VNN2           9.22E−05   Down
  NUCB2          9.22E−05   Down
  TIMP4          9.25E−05   Down
  TLE2           9.39E−05   Down
  PROS1          9.40E−05   Down
  EPHX1          9.74E−05   Down
  PGK1           9.76E−05   Down
  CLCN4          9.78E−05   Down
  YPEL5          9.90E−05   Down
  ERCC1          1.01E−04   Down
  TMC6           1.01E−04   Down
  RASGRP2        1.05E−04   Down
  SERPINB7       1.05E−04   Down
  ZFYVE21        1.05E−04   Down
  GAK            1.06E−04   Down
  GFOD1          1.07E−04   Down
  ARHGAP11A      1.07E−04   Down
  MAGIX          1.08E−04   Down
  SPAG6          1.16E−04   Down
  LRMP           1.17E−04   Down
  FLII           1.18E−04   Down
  SNED1          1.21E−04   Down
  PPOX           1.24E−04   Down
  UBA7           1.24E−04   Down
  BASP1          1.24E−04   Down
  IGJ            1.27E−04   Down
  C5orf4         1.32E−04   Down
  CTNS           1.34E−04   Down
  TEX264         1.35E−04   Down
  ABHD6          1.36E−04   Down
  TIMM13         1.39E−04   Down
  CCDC28A        1.40E−04   Down
  P4HTM          1.40E−04   Down
  IFIH1          1.43E−04   Down
  HIP1R          1.44E−04   Down
  STS            1.46E−04   Down
  ATP7B          1.46E−04   Down
  STAG3          1.54E−04   Down
  ZNF137P        1.56E−04   Down
  ZNF528         1.57E−04   Down
  TMEM9B         1.57E−04   Down
  PACRG          1.57E−04   Down
  DEPDC5         1.63E−04   Down
  CCDC81         1.65E−04   Down
  PRIM2          1.70E−04   Down
  RPS6KA1        1.72E−04   Down
  C14orf1        1.73E−04   Down
  CDT1           1.74E−04   Down
  NLRP1          1.76E−04   Down
  LPPR3          1.77E−04   Down
  ANKHD1         1.77E−04   Down
  CD52           1.79E−04   Down
  TCL1A          1.79E−04   Down
  ERCC5          1.79E−04   Down
  RNASET2        1.81E−04   Down
  KRT7           1.81E−04   Down
  FAM184A        1.81E−04   Down
  TMEM132A       1.81E−04   Down
  C11orf16       1.82E−04   Down
  CAMTA1         1.82E−04   Down
  HDC            1.93E−04   Down
  NIPSNAP3B      1.96E−04   Down
  LIMD2          1.98E−04   Down
  BAP1           2.02E−04   Down
  ZNF821         2.06E−04   Down
  ZBBX           2.09E−04   Down
  ZCWPW1         2.18E−04   Down
  TNNC2          2.18E−04   Down
  CALM1          2.22E−04   Down
  MAPK14         2.23E−04   Down
  SEL1L3         2.26E−04   Down
  VTI1B          2.28E−04   Down
  P2RX5          2.28E−04   Down
  CHAF1A         2.29E−04   Down
  SGTA           2.30E−04   Down
  MNS1           2.35E−04   Down
  FYCO1          2.35E−04   Down
  IL33           2.35E−04   Down
  SCUBE2         2.38E−04   Down
  TRIM24         2.41E−04   Down
  HSD17B2        2.42E−04   Down
  RASAL1         2.42E−04   Down
  ANXA11         2.44E−04   Down
  B3GNT3         2.44E−04   Down
  GLT8D1         2.45E−04   Down
  BCAR3          2.45E−04   Down
  ZBTB16         2.47E−04   Down
  ADRA2A         2.49E−04   Down
  USP19          2.51E−04   Down
  RARRES2        2.51E−04   Down
  SLC46A3        2.60E−04   Down
  MAGOHB         2.62E−04   Down
  SIRT3          2.63E−04   Down
  STAP1          2.64E−04   Down
  INPP4B         2.66E−04   Down
  PEPD           2.66E−04   Down
  JHDM1D         2.80E−04   Down
  COBL           2.80E−04   Down
  ITIH4          2.81E−04   Down
  DOCK3          2.84E−04   Down
  ADH1C          2.86E−04   Down
  C11orf2        2.87E−04   Down
  RHOBTB2        3.00E−04   Down
  SNW1           3.01E−04   Down
  CD79A          3.02E−04   Down
  TMC5           3.06E−04   Down
  ALDH3B1        3.14E−04   Down
  CDC14A         3.22E−04   Down
  SNTA1          3.23E−04   Down
  LYN            3.32E−04   Down
  LTF            3.33E−04   Down
  MLYCD          3.41E−04   Down
  DNAI1          3.45E−04   Down
  C1orf115       3.45E−04   Down
  CBX6           3.46E−04   Down
  KCNJ12         3.63E−04   Down
  ZBTB25         3.65E−04   Down
  UNC93B1        3.69E−04   Down
  C7orf44        3.72E−04   Down
  KIAA0125       3.80E−04   Down
  PARP3          3.94E−04   Down
  LOC284244      3.99E−04   Down
  FOLR1          3.99E−04   Down
  PPFIA4         4.13E−04   Down
  PKIG           4.15E−04   Down
  MOAP1          4.17E−04   Down
  C17orf59       4.24E−04   Down
  EFHC1          4.26E−04   Down
  CRISP2         4.26E−04   Down
  ANK2           4.29E−04   Down
  RHOH           4.40E−04   Down
  APOD           4.45E−04   Down
  TFEB           4.49E−04   Down
  PAIP2B         4.49E−04   Down
  CREBZF         4.52E−04   Down
  OCEL1          4.64E−04   Down
  SNX3           4.72E−04   Down
  TFB2M          4.82E−04   Down
  ALDH6A1        4.90E−04   Down
  RPGRIP1        4.93E−04   Down
  PNMA1          5.02E−04   Down
  TCEB1          5.18E−04   Down
  ATP5L          5.25E−04   Down
  LOC728855      5.28E−04   Down
  RPL36AL        5.52E−04   Down
  XRCC4          5.69E−04   Down
  TMEM63A        5.74E−04   Down
  C9orf9         5.92E−04   Down
  SLC15A2        6.00E−04   Down
  FAIM3          6.20E−04   Down
  VAV1           6.20E−04   Down
  CHKB           6.24E−04   Down
  CP             6.41E−04   Down
  PAF1           6.53E−04   Down
  MAGED2         6.58E−04   Down
  RRAD           6.58E−04   Down
  TXNIP          6.64E−04   Down
  ZFP161         6.79E−04   Down
  DIO1           6.79E−04   Down
  PTGER2         6.81E−04   Down
  SATB1          6.82E−04   Down
  PRR15L         6.82E−04   Down
  TRADD          6.87E−04   Down
  SLC1A1         6.88E−04   Down
  CHD7           7.19E−04   Down
  CRYM           7.20E−04   Down
  C7             7.20E−04   Down
  RBM38          7.34E−04   Down
  WWP2           7.40E−04   Down
  DTYMK          7.48E−04   Down
  OR7E47P        7.52E−04   Down
  NIP7           7.54E−04   Down
  FAM50B         7.57E−04   Down
  XPA            7.58E−04   Down
  KLHL7          7.73E−04   Down
  ZNF839         7.81E−04   Down
  SLC34A1        7.81E−04   Down
  FBXL2          7.85E−04   Down
  PLSCR4         7.92E−04   Down
  PBXIP1         7.93E−04   Down
  NAT6           7.94E−04   Down
  PPIL2          7.97E−04   Down
  KLHL36         8.19E−04   Down
  MAN2B2         8.24E−04   Down
  EHD1           8.42E−04   Down
  GPR183         8.75E−04   Down
  MFAP4          8.84E−04   Down
  HCLS1          8.99E−04   Down
  APEH           9.01E−04   Down
  LOC100129973   9.17E−04   Down
  DPAGT1         9.23E−04   Down
  TREX1          9.39E−04   Down
  PPP3CC         9.39E−04   Down
  ATG4A          9.44E−04   Down
  LY9            9.49E−04   Down
  TERF2IP        9.53E−04   Down
  HSPA9          9.53E−04   Down
  ITGA7          9.61E−04   Down
  CAPNS1         9.63E−04   Down

FDR: false discovery rate

**Source of support:** Departmental sources

![miRNA-mRNA interaction network of NPC. (**A**) Down-regulation miRNA and up-regulation mRNA interaction network. The green and blue diamond nodes represent down-regulation, and red and blue circular nodes represent up-regulation. (**B**) Up-regulation miRNA and down-regulation mRNA interaction network. The green and blue circular nodes represent down-regulation, and the red and blue diamond nodes represent up-regulation. Circular nodes represent mRNAs and diamond nodes represent miRNAs. Solid lines indicate interaction associations between the miRNAs and mRNAs. The blue diamond nodes and blue circular nodes represent verified miRNA and mRNA through qRT-PCR.](medscimonit-22-2215-g001){#f1-medscimonit-22-2215}

![miRNA and mRNA expression level in NPC and control tissues by qRT-PCR. (**A**) hsa-miR-632 and CD22; (**B**) hsa-miR-205 and PIGR; (**C**) hsa-miR-18b and SMPD3; (**D**) hsa-miR-34b and CDC6; (**E**) hsa-miR-130a and DTX4. Control tissues mean adjacent cancer tissues of NPC.](medscimonit-22-2215-g002){#f2-medscimonit-22-2215}

###### 

Genes and primers for qRT-PCR.

  miRNA/mRNA                         Primer sequence (5′to3′)
  ---------------------------------- -----------------------------------
  SMPD3                              Forward-CCAACAAGTGTAACGACGATGCC
  Reverse-CGCTGGACGAGGAGGTAGATTTTC   
  CD22                               Forward-ATGCCGATTCGAGAAGGAGACAC
  Reverse-CCACGAGCACCAACTATTACAAGC   
  DTX4                               Forward-AGAAAGGTAAAACCCCAGAGGAAGT
  Reverse-ATGGCAACCAAGCAGTAGATGTG    
  CDC6                               Forward-TTGAGCCAAGAAGGAGCACAAGATT
  Reverse-CTTCCAAGAGCCCTGAAAGTGACA   
  PIGR                               Forward-AGGTGCTAGACTCTGGTTTTCGG
  Reverse-TCTGCTCCCATCGGCTTGA        
  β-actin                            Forward-ACTTAGTTGCGTTACACCCTT
  Reverse-GTCACCTTCACCGTTCCA         
  hsa-Mir-205                        Forward-TCCTTCATTCCACCGGAGTCTG
  hsa-Mir-18b                        Forward-TAAGGTGCATCTAGTGCAGTTAGAA
  hsa-Mir-632                        Forward-GTGTCTGCTTCCTGTGGG
  hsa-Mir-130a                       Forward-CAGTGCAATGTTAAAAGGGC
  hsa-Mir-34b                        Forward-CAATCACTAACTCCACTGCCAT
  U6                                 Forward-CTCGCTTCGGCAGCACA
  Reverse-AACGCTTCACGAATTTGCGT       

###### 

Characteristics of mRNA and miRNA expression profiling of the nasopharyngeal carcinoma.

  GEO ID                           Platform                                                                                                   Samples (N:P)   Time   Author
  -------------------------------- ---------------------------------------------------------------------------------------------------------- --------------- ------ ------------
  **mRNA expression profiling**                                                                                                                                      
  GSE53819                         GPL6480Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version)                      18:18           2014   Qian CN
  GSE13597                         GPL96\[HG-U133A\] Affymetrix Human Genome U133A Array                                                      3:25            2009   Wei W
  GSE12452                         GPL570\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                                       10:31           2008   Ahlquist P
  **miRNA expression profiling**                                                                                                                                     
  GSE32906                         GPL11350 Illumina Custom Prostate Cancer DASL Panel miRNA                                                  6:16            2014   Luo Z
  GSE46172                         GPL16770Agilent-031181 Unrestricted_Human_miRNA_V16.0_Microarray (miRBase release 16.0 miRNA ID version)   4:4             2013   Bethony JM
  GSE22587                         GPL8933Illumina Human Beta-version microRNA expression BeadChip                                            4:8             2012   YANG S
  GSE32960                         GPL14722microRNA array                                                                                     18:312          2012   Ma J
  GSE36682                         Human miRNA 1K                                                                                             6:62            2012   Wei R

N -- normal samples; P -- patients' samples.

###### 

Significantly dysregulated miRNAs.

  miRNAs                  p-value    FDR
  ----------------------- ---------- ----------
  Up-regulated miRNAs                
   hsa-miR-205            0.00E+00   0.00E+00
   hsa-miR-196b           1.58E-05   1.85E-03
   hsa-miR-632            8.13E-05   3.56E-03
   hsa-miR-18b            7.37E-05   3.56E-03
   hsa-miR-93             3.81E-04   9.52E-03
   hsa-miR-326            3.78E-04   9.52E-03
   hsa-miR-210            3.18E-04   9.52E-03
   hsa-miR-376a\*         1.19E-03   2.46E-02
   hsa-miR-200c           1.64E-03   3.02E-02
   hsa-miR-18a\*          2.26E-03   3.77E-02
   hsa-miR-542-3p         2.60E-03   4.09E-02
   hsa-miR-9\*            3.47E-03   4.49E-02
  Down-regulated miRNAs              
   hsa-miR-130a           2.02E-11   3.54E-09
   hsa-let-7a             3.18E-05   2.78E-03
   hsa-miR-34b            4.60E-05   3.22E-03
   hsa-let-7e             7.38E-05   3.56E-03
   hsa-let-7d             1.46E-04   5.67E-03
   hsa-miR-30d            2.24E-04   7.83E-03
   hsa-miR-146a           3.31E-04   9.52E-03
   hsa-miR-98             1.09E-03   2.46E-02
   hsa-miR-10b            1.18E-03   2.46E-02
   hsa-miR-138            1.45E-03   2.83E-02
   hsa-miR-31             1.75E-03   3.05E-02
   hsa-miR-363            2.69E-03   4.09E-02
   hsa-miR-564            2.90E-03   4.23E-02
   hsa-let-7g             3.09E-03   4.33E-02
   hsa-miR-29a            3.31E-03   4.45E-02

FDR -- false discovery rate.

###### 

GO function enrichment analysis of differentially expressed miRNA target genes (top 15).

  GO ID                    GO Term                                                                                     Count   P-value    FDR
  ------------------------ ------------------------------------------------------------------------------------------- ------- ---------- ----------
  **Biological process**                                                                                                                  
  GO: 0000280              Nuclear division                                                                            7       3.05E-05   1.48E-01
  GO: 0044839              Cell cycle G2/M phase transition                                                            6       4.02E-05   9.76E-02
  GO: 0000086              G2/M transition of mitotic cell cycle                                                       6       4.02E-05   6.50E-02
  GO: 0007067              Mitotic nuclear division                                                                    6       7.71E-05   9.37E-02
  GO: 0022617              Extracellular matrix disassembly                                                            6       8.75E-05   8.50E-02
  GO: 0030574              Collagen catabolic process                                                                  6       8.75E-05   7.08E-02
  GO: 0044243              Multicellular organismal catabolic process                                                  6       8.75E-05   6.07E-02
  GO: 0048285              Organelle fission                                                                           7       9.46E-05   5.74E-02
  GO: 0051301              Cell division                                                                               9       1.45E-04   7.83E-02
  GO: 0044763              Single-organism cellular process                                                            191     1.87E-04   9.08E-02
  GO: 1903047              Mitotic cell cycle process                                                                  12      2.80E-04   1.24E-01
  GO: 0044772              Mitotic cell cycle phase transition                                                         9       2.84E-04   1.15E-01
  GO: 0044770              Cell cycle phase transition                                                                 9       2.84E-04   1.06E-01
  GO: 0051726              Regulation of cell cycle                                                                    41      2.92E-04   1.01E-01
  GO: 0032963              Collagen metabolic process                                                                  6       3.49E-04   1.13E-01
  **Cellular component**                                                                                                                  
  GO: 0044446              Intracellular organelle part                                                                159     1.95E-05   1.09E-02
  GO: 0044422              Organelle part                                                                              162     3.62E-05   1.01E-02
  GO: 0005581              Collagen trimer                                                                             5       6.87E-05   1.28E-02
  GO: 0005829              Cytosol                                                                                     42      4.30E-04   6.01E-02
  GO: 0044424              Intracellular part                                                                          222     7.32E-04   8.19E-02
  **Molecular function**                                                                                                                  
  GO: 0003824              Catalytic activity                                                                          88      1.09E-04   1.06E-01
  GO: 0016787              Hydrolase activity                                                                          7       1.75E-04   8.55E-02
  GO: 0004000              Adenosine deaminase activity                                                                2       5.17E-04   1.68E-01
  GO: 0016814              Hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines   2       5.17E-04   1.26E-01

FDR -- false discovery rate.

###### 

KEGG pathway enrichment analysis of differentially expressed miRNA target genes (top 15).

  KEGG ID    KEGG term                                Count   FDR        Genes
  ---------- ---------------------------------------- ------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa05200   Pathways in cancer                       27      1.78E-11   CCNE2, STAT1, KITLG, RARB, BIRC5, E2F3, EPAS1, FZD7, BMP2, NRAS, COL4A5, CDK4, NFKBIA, RAD51, WNT2, BID, FZD4, MYC, PIK3CD, ITGAV, BRCA2, ITGB1, ARNT2, ZBTB16, HDAC2, PTGS2, MMP1
  hsa04110   Cell cycle                               14      1.48E-07   CCNE2, ESPL1, CDC14A, GADD45A, E2F3, CHEK1, CCND2, CDK4, CDC25C, CDC6, RBL2, MYC, CDC25A, HDAC2
  hsa05222   Small cell lung cancer                   11      9.81E-07   CCNE2, RARB, E2F3, COL4A5, CDK4, NFKBIA, MYC, PIK3CD, ITGAV, ITGB1, PTGS2
  hsa04060   Cytokine-cytokine receptor interaction   16      3.08E-05   INHBB, IL15RA, KITLG, IL15, BMP2, CXCL3, CLCF1, TNFSF15, PRLR, CCR1, GHR, CD40LG, CCL8, TNFRSF9, TNFSF4, CCR6
  hsa04662   B cell receptor signaling pathway        8       3.15E-04   CD22, CD79A, NRAS, NFKBIA, LYN, PIK3CD, PPP3CA, CD19
  hsa05162   Measles                                  10      3.87E-04   CCNE2, STAT1, EIF2AK2, TNFAIP3, CCND2, CDK4, NFKBIA, PIK3CD, OAS3, ADAR
  hsa04115   p53 signaling pathway                    5       4.14E-04   CCNE2, GADD45A, CHEK1, CCND2, CDK4
  hsa04640   Hematopoietic cell lineage               8       4.18E-04   CD22, KITLG, CD1D, TFRC, CD1C, CD19, MS4A1, CR1
  hsa05220   Chronic myeloid leukemia                 7       6.01E-04   E2F3, NRAS, CDK4, NFKBIA, MYC, PIK3CD, HDAC2
  hsa04630   Jak-STAT signaling pathway               10      7.27E-04   IL15RA, STAT1, IL15, CCND2, CLCF1, SOCS5, PRLR, MYC, PIK3CD, GHR
  hsa05140   Leishmaniasis                            4       8.58E-04   STAT1, NFKBIA, ITGB1, PTGS2
  hsa05160   Hepatitis C                              9       8.98E-04   STAT1, EIF2AK2, CLDN8, NRAS, NFKBIA, TRADD, PIK3CD, MAPK14, OAS3
  hsa05340   Primary immunodeficiency                 5       9.13E-04   CD79A, ADA, CD40LG, CD19, UNG
  hsa05219   Bladder cancer                           3       1.22E-03   E2F3, CDK4, MYC
  hsa04610   Complement and coagulation cascades      6       1.77E-03   PLAUR, PROS1, C3AR1, C7, CR1, PLAU

FDR -- false discovery rate.
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